Plain-English translation of NCT07887971 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called [225Ac]Ac-AKY-2519, which is a radioactive medication designed to find and attack cancer cells that have a specific protein marker on their surface. The medication is given as an infusion through a vein. Researchers are studying whether this treatment is safe and how well it works in patients with advanced solid tumors, including lung cancer, prostate cancer, head and neck cancer, and other types.
Many advanced cancers have a protein on their surface called B7-H3 that current treatments don't specifically target. This medication is designed to deliver radiation directly to cancer cells that have this protein, which could potentially be more effective and cause less harm to healthy cells than traditional chemotherapy.
You likely qualify if…
You likely don't qualify if…
The study has two parts: first, researchers will test increasing doses of the medication in a small group to find the right dose and watch for side effects; then, they will expand to two larger groups to better understand how well the treatment works. You would receive the radioactive medication as an infusion through a vein and return for regular visits to have blood tests, imaging scans, and check-ups to monitor your cancer and any side effects.
AI-generated summary from trial data · Oct 31, 2026 · Not medical advice
United States